On Wednesday, Shares of General Electric Company (NYSE:GE), gained 0.61% to $26.26.
In developed countries like the U.S., Europe and parts of Asia, healthcare leaders are trying to optimize efficiency, systems integration, data analytics and achieve greater productivity. In emerging economies, enabling access to affordable, basic primary care is often the most pressing concern. Healthcare systems around the world face a wide range of difficult challenges. All could benefit from training and education solutions focused specifically on their particular needs.
To assist address this issue, GE Healthcare recently declared a plan to invest more than $1 billion over five years in the development of its educational offerings to reach more than two million healthcare professionals worldwide by 2020, assisting them improve healthcare from within through improved training programs and solutions for physicians, radiologists, technologists, midwives, nurses, biomedical engineers and beyond. Solutions will be geared to meet local needs and will comprise new clinical, product application, technical and leadership training and education.
General Electric Company (GE) operates as an infrastructure and financial services company worldwide. The company’s Power and Water segment offers gas, steam and aeroderivative turbines, nuclear reactors, generators, combined cycle systems, controls, and related services; wind turbines.
Shares of Baxter International Inc. (NYSE:BAX), inclined 1.08% to $38.50, during its last trading session.
Baxter International declared a regular quarterly dividend of $0.115 per Baxter common share. This cash dividend is payable on October 1, 2015 to shareholders of record as of September 4, 2015.
This dividend represents the new quarterly dividend rate for Baxter following its successful spin-off of its biopharmaceuticals business, Baxalta Incorporated, on July 1, 2015. Over its 84-year history, Baxter has consistently paid a dividend to shareholders and followed a disciplined approach to capital allocation that balances reinvestment in the businesses with returning noteworthy value to shareholders.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.